A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma

Inclusion Criteria:

- Severity of Disease: The patient has persistent asthma, with an forced expiratory
volume in 1 second (FEV1) 40%-85% of the value predicted for age, height, sex, and
race as per the National Health and Nutrition Examination Survey (NHANES III)
reference values at screening visit (SV) (Hankinson et al 1999).

- Current asthma therapy: The patient is currently being treated with 1 of the
following:

1) inhaled corticosteroids (ICSs) at a stable daily dose of less than or equal to 220
mcg/day fluticasone propionate via metered dose inhaler (MDI) or equivalent for a
minimum of 4 weeks (28 days) before screening visit, or 2) a stable daily dosage of
non-corticosteroid therapy, including leukotriene modifiers, theophylline, chromones,
or short-acting beta-2 agonists (SABAs) alone or in combination for a minimum of 4
weeks (28 days) before screening visit (SV).

- Reversibility of disease: The patient has demonstrated at least 15% and at least 200
mL increase from baseline FEV1 (patients age 18 and older) within 30 minutes after 2-4
inhalations of albuterol/salbutamol hydrofluoroalkane (HFA) MDI (90 mcg ex-actuator)
or equivalent at SV or on retesting. - Other criteria apply, please contact the
investigator for more information

Exclusion Criteria:

- The patient has a history of life-threatening asthma, defined for this protocol as an
asthma episode that required intubation and/or was associated with hypercapnea,
respiratory arrest, or hypoxic seizures.

- The patient is a pregnant or lactating female or plans to become pregnant.

- The patient has a known hypersensitivity to any corticosteroid or any of the
excipients in the study drug or rescue medication formulation.

- The patient currently smokes or has a smoking history of 10 pack-years or more (a
pack-year is defined as smoking 1 pack of cigarettes/day for 1 year). The patient may
not have used tobacco products within the past year.

- The patient has had an asthma exacerbation requiring oral corticosteroids within 1
month before SV, or has had any hospitalization for asthma within 2 months before SV.

- The patient has historical or current evidence of a clinically significant disease.
Significant disease is defined as any disease that in the medical judgment of the
investigator would put the safety of the patient at risk through participation or that
could affect the efficacy or safety analysis if the disease/condition worsened during
the study.

- Other criteria apply, please contact the investigator for more information